Type 1 insulin-like growth factor receptor (IGF-IR) is deregulated in solid tumors. Cixutumumab, a monoclonal antibody that inhibits IGF-IR activity, was investigated in combination with pemetrexed/cisplatin in the front-line setting.
Brief Report: An Open-Label, Multicenter, Randomized, Phase II Study of Cisplatin and Pemetrexed With or Without Cixutumumab (IMC-A12) as a First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
NOVELLO, Silvia
First
;SCAGLIOTTI, Giorgio Vittorio;
2017-01-01
Abstract
Type 1 insulin-like growth factor receptor (IGF-IR) is deregulated in solid tumors. Cixutumumab, a monoclonal antibody that inhibits IGF-IR activity, was investigated in combination with pemetrexed/cisplatin in the front-line setting.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
24.Brief Report An Open-Label Multicenter Randomized Phase II Study.pdf
Open Access dal 31/07/2016
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
1.01 MB
Formato
Adobe PDF
|
1.01 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
